Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Brief description of study

Primary Objective:

  • To describe the safety profile of the SP MenB vaccine formulations and the 2 licensed MenB comparator vaccines in healthy adults, adolescents, toddlers and infants, when administered alone (Stages 1-4) or concomitantly with MenQuadfiTM (MenACYW conjugate vaccine) (for Stages 2-4 only), and with age-appropriated routine pediatric vaccines (for Stages 3-4 only)
    1. To describe the safety profile of the SP MenB vaccine formulations, Bexsero Vaccine and Trumenba Vaccine in healthy adults, and adolescents;
    2. To describe the safety profile of the SP MenB vaccine formulations and Bexsero Vaccine in toddlers and infants;
    3. To describe the safety profile of the SP MenB vaccine formulations,
  • when administered alone
  • when administered with MenQuadfiTM (MenACYW conjugate vaccine)
  • when administered with routine infant immunizations
  • To describe the immune response to the SP MenB vaccine formulations and the 2 licensed MenB comparator vaccines after the last dose of primary vaccination in healthy adults, adolescents, toddlers and infants, when administered alone, or concomitantly with MenQuadfi Vaccine or other routine vaccines, as measured by the serum bactericidal assay using human complement (hSBA) in the primary panel of MenB strains by Stage, by age group and by vaccine schedule

Secondary Objective:

  • To describe the immune response to the SP MenB vaccine formulations and the 2 licensed MenB comparator vaccines at each timepoint in healthy adults, adolescents, toddlers and infants, when administered alone or concomitantly with MenQuadfi Vaccine or other routine vaccines as measured by hSBA in the primary panel of MenB strains by Stage by age group and by vaccine schedule
  • To describe the immune response (breadth of coverage) in the secondary panel of MenB strains in participants (adults and adolescents) in Stage 1 and 2 after the last dose of the primary series in each group
  • To describe the persistence of immune response following primary series at D366, and immune response 1 month after a booster dose of the SP MenB vaccine given 1-year post-dose 1 (at D366) in a subset of adults and adolescents in Stage 2 who received SP MenB vaccine formulations, Bexsero Vaccine or Trumenba Vaccine as measured by hSBA in the primary panel of MenB strains by age group
  • To describe the immune response against meningococcal serogroups A, C, W and Y measured with hSBA in participants from each agegroup receiving MenQuadfi Vaccine

Study duration per participant will be approximately: 7 months for Stage 1 participants, 12 to 18.5 months for Stage 2 participants, 12 months for Stage 3 participants and 18 months for Stage 4 participants

In each vaccine group at each age group (Stage 1, 3 and 4 only), the first 5 participants enrolled (sentinels) will be assessed via early safety data review (ESDR) as a cohort for the evaluation of biological safety and overall safety profile for D01-D08 post dose 1. The safety data collected will be reviewed before proceeding with recruitment of remaining participants in each study group. Enrollment of remaining participants randomized to each group will be based on the outcome of the safety assessments of the sentinels: only a positive review outcome will allow the enrollment of the sentinel cohort of the respective lower age group.

Clinical Study Identifier: NCT04825223

You may be eligible for this study if you meet the following criteria:

  • Conditions: Meningococcal Immunisation
  • Age: Between 42 Years - 50 Years
  • Gender: Male or Female

Inclusion criteria :

        -For US: Aged 10 to 25 years on the day of inclusion ("10-25 years" means from the day of
        the 10th birthday to the day before the 26th birthday) For EU: Aged 42 to 89 days or 12 to
        18 months or 10 to 50 years on the day of inclusion ("42 to 89 days" means from 42 days
        after birth to the 89th day after birth; "12-18 months" means from the12th month after
        birth to the day before the 19th month after birth; "10-50 years" means from the day of the
        10th birthday to the day before the 51st birthday Participants or participant and
        parent/legally acceptable representative are able to attend all scheduled visits and to
        comply with all trial procedures Covered by health insurance (applicable depending on local
        regulations) Participants who are overtly healthy as determined by medical evaluation
        including medical history, physical examination, and judgement of the Investigator
        For adults: A female participant is eligible to participate if she is not pregnant or
        breastfeeding and one of the following conditions applies:
          -  Is of non-childbearing potential. To be considered of non-childbearing potential, a
             female must be post-menopausal for at least 1 year, or surgically sterile OR
          -  Is of childbearing potential and agrees to use an effective contraceptive method or
             abstinence from at least 4 weeks prior to the first study intervention administration
             until at least 4 weeks after the last study intervention administration.
        A female participant of childbearing potential must have a negative highly sensitive
        pregnancy test (urine or serum as required by local regulation) the day of any dose of
        study intervention
        For adolescents: A female participant is eligible to participate if she is not pregnant or
        breastfeeding and one of the following conditions applies:
          -  Is of non-childbearing potential. To be considered of non-childbearing potential, a
             female must be pre-menarche OR
          -  Is of childbearing potential and agrees to use an effective contraceptive method or
             abstinence from at least 4 weeks prior to the first study intervention administration
             until at least 4 weeks after the last study intervention administration A female
             participant of childbearing potential must have a negative highly sensitive pregnancy
             test (urine or serum as required by local regulation) the day of any dose of study
             intervention -For infants: Born at full term of pregnancy (≥37 weeks) and with a birth
             weight ≥2.5 kg or born after a gestation period of 27 through 36 weeks and medically
             stable as assessed by the investigator, based on the following definition: "Medically
             stable" refers to the condition of premature infants who do not require significant
             medical support or ongoing management for debilitating disease and who have
             demonstrated a clinical course of sustained recovery by the time they receive the
             first dose of study intervention - - -
        Exclusion criteria:
        -Known or suspected congenital or acquired immunodeficiency; or receipt of
        immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within
        the preceding 6 months or since birth for infants and toddlers; or long-term systemic
        corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within
        the past 3 months or since birth for infants and toddlers) History of any Neisseria
        meningitidis infection, confirmed either clinically, serologically, or microbiologically At
        high risk for meningococcal infection during the trial (specifically, but not limited to,
        participants with persistent complement deficiency, with anatomic or functional asplenia,
        or participants travelling to countries with high endemic or epidemic disease) Individuals
        with active tuberculosis Known systemic hypersensitivity to latex or to any of the vaccine
        components, or history of a life-threatening reaction to the vaccine(s) used in the trial
        or to a vaccine containing any of the same substances For adults and adolescents:
        Self-report of thrombocytopenia, contraindicating intra-muscular (IM) vaccination * For
        infants and toddlers: Laboratory-confirmed thrombocytopenia, or known thrombocytopenia, as
        reported by the parent/legally acceptable representative contraindicating intramuscular
        vaccination Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding
        inclusion, contraindicating IM vaccination For infants and toddlers: History of
        intussusception Receipt of any vaccine in the 4 weeks (28 days) preceding the first trial
        vaccination or planned receipt of any vaccine 4 weeks before to 4 weeks after each trial
        vaccination or study visit with collection of blood for immunogenicity assessments, except
        for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after
        any study vaccination. This exception includes monovalent pandemic influenza vaccines and
        multivalent influenza vaccines Previous vaccination against meningococcal B disease with
        either the study vaccines or another licensed or investigational vaccine (i.e., mono- or
        polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroup B) For
        infants and toddlers: Previous vaccination against meningococcal disease with either the
        study vaccines or any other licensed or investigational vaccine containing serogroups A, C,
        W, Y; or meningococcal serogroup B Receipt of immune globulins, blood or blood-derived
        products in the past 3 months or since birth for infants and toddlers Receipt of oral or
        injectable antibiotic therapy within 72 hours prior to the first immunogenicity blood draw
        For infants: Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis,
        hepatitis A, measles, mumps, rubella, varicella; and Haemophilus influenzae type b,
        Streptococcus pneumoniae, and /or rotavirus infection or disease, and receipt of more than
        1 previous dose of hepatitis B vaccine Participation at the time of study enrollment (or in
        the 4 weeks preceding the first trial vaccination) or planned participation during the
        present trial period in another clinical trial investigating a vaccine, drug, medical
        device, or medical procedure Chronic illness that, in the opinion of the investigator, is
        at a stage where it might interfere with trial conduct or completion Moderate or severe
        acute illness/infection (according to the investigator's judgment), febrile illness
        (temperature ≥ 38.0°C or ≥ 100.4°F). A prospective participant should not be enrolled in
        the study until the condition has resolved or the febrile event has subsided History of
        Guillain-Barré syndrome History of any neurologic disorders, including any seizures and
        progressive neurologic disorders Deprived of freedom by an administrative or court order,
        or in an emergency setting, or hospitalized involuntarily For adults and adolescents:
        Identified as an investigator or employee of the investigator or study center with direct
        involvement in the proposed study, or identified as an immediate family member (i.e.,
        parent, spouse, natural or adopted child) of the investigator or employee with direct
        involvement in the proposed study For infants and toddlers: Identified as a natural or
        adopted child of the Investigator or employee with direct involvement in the proposed study
        For adults and adolescents: Alcohol, prescription drug, or substance abuse that, in the
        opinion of the Investigator, might interfere with the study conduct or completion
        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.

Last updated on 09 Dec 2021

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250